Company Overview

About PW Medtech Group Limited (1358.HK)

 

   Since 10 March 2014, PW Medtech Group Limited has been selected as a constituent of Hang Seng Composite Index Series, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index-Consumer Goods, Hang Seng Global Composite Index, Hang Seng Mainland Consumer Goods Index and Hang Seng Broad Consumption Index.

 

   At present, the core business segments of PW Medtech Group is advanced infusion sets segment, which principally involves the manufacturing of precision filter infusion sets and non-PVC infusion sets. PW Medtech Group Limited has developed into the domestic giant of these two segments and owns several high-tech subsidiaries.

    

   Throughout the years, the “Fert” brand under the Group has been focusing on providing a safer and more efficient solution for infusion therapy. Fert Technology is the first domestic enterprise engaging in the research and development as well as manufacturing of precision filter infusion sets since 1990s and has participated in formulating the national standard of precision filter infusion sets products. As a leading enterprise in the field of infusion healthcare, Fert Technology has opened a new chapter in China’s development of safe infusion. These precision filter infusion sets can substantially mitigate the impact of insoluble particles in medical solution on patients during the process of infusion, thereby largely reduces the risk of complication. At the beginning of this century, Fert Technology is also one of the first three manufacturers in China which pioneered the use of non-PVC safe material to produce infusion sets. Such products can effectively replace traditional PVC infusion sets and avoid the potential adverse impact on patients caused by some harmful materials in traditional infusion sets. The rising awareness of the medical industry on the safety issue of infusion in recent years has particularly demonstrated the farsightedness of PW Medtech as a pioneering manufacturer of advanced infusion sets. The Group has maintained the second largest market share in the domestic advanced infusion sets market and ranked number one in Beijing market for years. In the future, PW Medtech will continue to place high importance on the field of infusion therapy and introduce new healthcare products such as disposable intravenous cannula to contribute to the safety and efficiency of medical healthcare industry.

    In order to allocate resources in a more effective manner and maximize corporate value, the Company entered into the Share Exchange Agreement with CBPO on October 12, 2017, pursuant to which, the Company agreed to subscribe for 16.66% of the enlarged issued share capital of CBPO in consideration of all the issued shares of Health Forward, which in turn owns 80% equity interest in Tianxinfu. CBPO enjoys a leading market position in the domestic blood product industry. Upon completion of the transaction on January 1, 2018, the Company became the single largest shareholder of CBPO. Following the completion of the share exchange transaction with China Biologic Products Holdings, Inc. (“CBPO”) in January 2018, the Group invested approximately US$80.72 million for the further acquisition of 800,000 shares in CBPO in August 2018 and increased its shareholding in CBPO to 6,321,000 shares. Currently, the Group remains as the single largest shareholder of CBPO holding approximately 16.06% of the issued share capital of CBPO. CBPO has an established plasma business with good track record and it is a leading producer in the blood products in mainland China. The Group believes that the strategic cooperation with CBPO can bring new blood for its business, which enables the Company to further diversify its business, optimize the business layout, solidify its market leading position and realise rapid growth.

   In November 2018, the new factory of the Group’s advanced infusion set business located at the Mafang Industrial Park (馬坊工業園區) officially commenced operation. Located in the southwest of Pinggu District, Beijing, the PRC, the new factory lies in the core area of Beijing-Tianjin-Hebei region and occupies a central location in Bohai Economic Rim, which is the “entry point” and serves as a “hub” for Beijing to integrate with the Beijing-Tianjin-Hebei region. 

    Apart from continue to focus on organic growth derived from its core business segments, the Group will also leverage on the synergy effect among research and development, distribution network and business operation through its outstanding acquisition and integration strategy. The Group aims to become a comprehensive platform for high-value medical consumables in China.

    Through years of effort, PW Medtech has not only established an extensive distribution network covering 31 provinces, cities and municipalities across China, but also built up a strong research and development team as well as a professional, mature and well-established management team with each key person-in-charge having years of working and management experience in their respective fields. Building on the platform of existing businesses, PW Medtech will continue to explore and innovate. By adhering to the ideology of focusing on medical care and revering life, the Group will make its best effort to contribute to China’s medical industry. Our people hold the belief that only integrity can create our prestigious brands, only innovation can make the market leader, only professionalism can provide intimate care for health.